Background: Klebsiella pneumoniae is a cause of mild to life threatening infections. Thernbacterium poses an urgent public health threat because it has the potential to become resistant tornvirtually all categories of antimicrobials available. Multidrug resistant K. pneumoniae has causedrnnosocomial outbreaks in different continents. Little is known concerning the antimicrobialrnresistance profiles of K. pneumoniae in Ethiopia. rnObjective: The aim of this study was to determine the phenotypic antimicrobial resistance profiles ofrnK. pneumoniae isolated from patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. rnMethodology: A cross-sectional study was conducted on antimicrobial resistance profiles of 132rnK. pneumoniae, isolated from patients from September 2018 to February 2019. Identification ofrnK. pneumoniae was done by examining gram stain, colony characterstics on MacConkey agar,rn5% sheep blood agar and biochemical tests. Antimicrobial susceptibility testing was done by rnKirby-Bauer disc diffusion technique. Extended spectrum ï¢-lactamase (ESBL) andrncarbapenemase production was confirmed by combined disc test and modified carbapenemaserninactivation method, respectively. Data was double entered using Epidata 3.1 and exported tornSPSS version 25 software for analysis. Binary logistic regression and Chi-Square or Fisher'srnexact test were used to measure the association. P-value less than 0.05 was considered asrnstatistically significant. rnResults: Among the total K. pneumoniae isolates high frequency of resistance was observed torncefotaxime and ceftriaxone 128 (97%), trimethoprim-sulfamethoxazole 124 (93.9%) andrncefepime 111 (84.1%). Most frequent susceptibility was observed to amikacin 123 (93.2%),rnimipenem 107 (81.1%), meropenem 96 (72.7%) and ertapenem 93 (70.5%). Majority 130rn(98.5%) of the isolates were multidrug resistant (MDR). Two isolates showed complete nonsusceptibilityrnrnto all antimicrobial agents tested. The magnitude of ESBL and carbapenemasernproduction was 77.3% and 21.2%, respectively. Of the total (n=30) non-ESBL producers, 73.3%rnwere carbapenemase producers. Non-ESBL producers showed high resistance to imipenemrn(53.3%), meropenem (80%) and ertapenem (83.3%). Higher proportion of ESBL production wasrnobserved in those aged below 5 years than those 18 to 45 years and among those admitted to thernintensive care units and pediatric wards than those in medical wards. Previous use ofrncarbapenems was associated with carbapenemase production (P